MMWR Morb Mortal Wkly Rep. 2020 Jul 24;69(29):960-964. doi: 10.15585/mmwr.mm6929e1.
Population prevalence of persons infected with SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19), varies by subpopulation and locality. U.S. studies of SARS-CoV-2 infection have examined infections in nonrandom samples (1) or seroprevalence in specific populations* (2), which are limited in their generalizability and cannot be used to accurately calculate infection-fatality rates. During April 25-29, 2020, Indiana conducted statewide random sample testing of persons aged ≥12 years to assess prevalence of active infection and presence of antibodies to SARS-CoV-2; additional nonrandom sampling was conducted in racial and ethnic minority communities to better understand the impact of the virus in certain racial and ethnic minority populations. Estimates were adjusted for nonresponse to reflect state demographics using an iterative proportional fitting method. Among 3,658 noninstitutionalized participants in the random sample survey, the estimated statewide point prevalence of active SARS-CoV-2 infection confirmed by reverse transcription-polymerase chain reaction (RT-PCR) testing was 1.74% (95% confidence interval [CI] = 1.10-2.54); 44.2% of these persons reported no symptoms during the 2 weeks before testing. The prevalence of immunoglobulin G (IgG) seropositivity, indicating past infection, was 1.09% (95% CI = 0.76-1.45). The overall prevalence of current and previous infections of SARS-CoV-2 in Indiana was 2.79% (95% CI = 2.02-3.70). In the random sample, higher overall prevalences were observed among Hispanics and those who reported having a household contact who had previously been told by a health care provider that they had COVID-19. By late April, an estimated 187,802 Indiana residents were currently or previously infected with SARS-CoV-2 (9.6 times higher than the number of confirmed cases [17,792]) (3), and 1,099 residents died (infection-fatality ratio = 0.58%). The number of reported cases represents only a fraction of the estimated total number of infections. Given the large number of persons who remain susceptible in Indiana, adherence to evidence-based public health mitigation and containment measures (e.g., social distancing, consistent and correct use of face coverings, and hand hygiene) is needed to reduce surge in hospitalizations and prevent morbidity and mortality from COVID-19.
人群中感染严重急性呼吸综合征冠状病毒 2(导致 2019 年冠状病毒病(COVID-19)的病毒)的流行率因亚人群和地点而异。美国对 SARS-CoV-2 感染的研究检查了非随机样本中的感染(1)或特定人群的血清流行率*(2),这些研究的普遍性有限,不能用于准确计算感染病死率。2020 年 4 月 25 日至 29 日,印第安纳州对≥12 岁的人群进行了全州随机抽样检测,以评估活动性感染的流行率和 SARS-CoV-2 抗体的存在情况;在少数族裔社区中还进行了非随机抽样,以更好地了解该病毒在某些少数族裔人群中的影响。使用迭代比例拟合方法,根据对答复的调整来估计非反应率,以反映州人口统计数据。在随机抽样调查的 3658 名非机构化参与者中,通过逆转录-聚合酶链反应(RT-PCR)检测确认的全州范围内 SARS-CoV-2 感染的估计点流行率为 1.74%(95%置信区间[CI]为 1.10-2.54);这些人中 44.2%在检测前两周内报告没有症状。免疫球蛋白 G(IgG)血清阳性率(表示过去感染)为 1.09%(95%CI=0.76-1.45)。印第安纳州当前和既往 SARS-CoV-2 感染的总流行率为 2.79%(95%CI=2.02-3.70)。在随机样本中,西班牙裔和那些报告家中有以前曾被医疗保健提供者告知患有 COVID-19 的接触者的人,总体流行率更高。截至 4 月底,估计有 187802 名印第安纳州居民目前或以前感染过 SARS-CoV-2(比确诊病例数高 9.6 倍[17792])(3),有 1099 人死亡(感染病死率=0.58%)。报告的病例数仅占估计总感染人数的一小部分。鉴于印第安纳州仍有大量易感人群,需要遵守循证公共卫生缓解和遏制措施(例如,保持社交距离、持续正确使用口罩和手部卫生),以减少住院人数激增,并防止 COVID-19 导致的发病率和死亡率。